A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR
A Non-interventional, Multi-center, Observational Post Authorization Safety Study of Patients With Relapse/Refractory Multiple Myeloma Treated With Lenalidomide in Turkey
Sponsor: Celgene
Listed as NCT02387879, this observational or N/A phase trial focuses on Multiple Myeloma and remains ongoing. Sponsored by Celgene, it has been updated 12 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Unknown
-
Sep 2024 — Sep 2025 [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Feb 2023 — Jul 2024 [monthly]
Unknown Status
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Feb 2023 [monthly]
Active Not Recruiting
▶ Show 7 earlier versions
-
Oct 2019 — Jan 2021 [monthly]
Active Not Recruiting
-
Jun 2018 — Oct 2019 [monthly]
Active Not Recruiting
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
May 2017 — Apr 2018 [monthly]
Recruiting NA
-
Feb 2017 — May 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adana, Turkey (Türkiye) , Ankara, Turkey (Türkiye) , Antalya, Turkey (Türkiye) , Bursa, Turkey (Türkiye) , Denizli, Turkey (Türkiye) , Diyarbakır, Turkey (Türkiye) , Edirne, Turkey (Türkiye) , Eskişehir, Turkey (Türkiye) , Gaziantep, Turkey (Türkiye) , Istanbul, Turkey (Türkiye) and 10 more locations